A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations

(E-pub Ahead of Print)

Author(s): Akash Gadgade, Ashok Shenoy*, Ashwin Kamath, Priyanka Kamath, Prabha Adhikari, Nishith RS, Sanjay Hadigal, Srikant N, Nandita Shenoy, Mukta N Chowta.

Journal Name: Current Diabetes Reviews

Become EABM
Become Reviewer

Abstract:

Background The specific treatment recommendations for type 2 diabetes mellitus (T2DM) differ based on a particular guideline. The goal of pharmacotherapy is to achieve the target HbA1c and fasting and postprandial blood glucose levels and avoid disease complications.

Objective To evaluate the profile of T2DM patients on different antidiabetic treatment regimens and the factors leading to dose escalation in these patients.

Method A prospective descriptive study was conducted at Kasturba Medical College Hospital, Mangalore, a tertiary care teaching hospital, over a period of one year. The study population was patients with T2DM for ≥5 years. The demographic and clinical data was collected during the baseline and follow-up visits.

Results Of the 119 patients studied, 59.7% were males; 32.8% were ≥65 years of age. A significant decrease in the fasting blood glucose (FBG) on follow-up was seen (p = 0.028) in patients on sulfonylurea and metformin combination. A significant decrease in the glycated haemoglobin (HbA1c) was seen in patients on sulfonylurea with metformin and pioglitazone (p = 0.011); sulfonylurea with metformin, pioglitazone, and sitagliptin (p = 0.026); and metformin with insulin (p = 0.001). Patients who received dose escalation had a longer duration of the disease (p = 0.042), higher FBG (p = 0.039) and HbA1c (p = 0.05).

Conclusion A combination of metformin with sulfonylurea was the preferred first-line treatment; insulin was added when the HbA1c was >9. Patients who received dose escalation had a longer duration of the disease and higher FBG and HbA1c.

Keywords: Diabetes mellitus, pharmacotherapy, fixed-dose combination, metformin, sulfonylurea, glycated hemoglobin

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573399815666190619125857
Price: $95

Article Metrics

PDF: 2